Home › RegulatoryALNYLAM PHARMACEUTICALS, INC. - 10-Q FilingAlnylam Pharmaceuticals reported Q2 revenue of $5.2B, up 12% YoY and above guidance.SEC EDGAR · July 30, 2026, 12:12 UTCTickers: $ALNY Read the full article at SEC EDGAR